Table 4. Univariate Sensitivity Analysis for Cost-effectiveness of Voriconazole Versus Fluconazole in Patients With Allogeneic Hematopoietic Cell Transplants^a.

	Cost per IFI Avoided			Cost per Life-year Gained
Scenario	Total Study	AML	Other Diagnosisb	Total Study	AML	Other Diagnosisb
12 Months
Base case	$812,990	$66,919	Dominatedc	Dominatedc	$5,453	Dominatedc
Generic oral voriconazole	$384,099	$9,683	Dominatedc	Dominatedc	$789	Dominatedc
Alternative IFI treatment costs	$881,219	$71,210	Dominatedc	Dominatedc	$5,802	Dominatedc
6 Months
Base case	$196,622	$34,576	$2,872,064	n/a	n/a	n/a
Generic oral voriconazole	$78,629	Dominantd	$1,498,005	n/a	n/a	n/a
Alternative IFI treatment costs	$210,202	$44,503	$2,922,074	n/a	n/a	n/a

AML = acute myeloid leukemia; IFI = invasive fungal infection.

^aCosts in 2011 US$.

^b“Other diagnosis” underlying diseases subpopulation.

^cDominated means that treatment with voriconazole was both more expensive and resulted in either fewer fungal infections avoided or fewer estimated life years than treatment with fluconazole.

^dDominant means that treatment with voriconazole was both less expensive and resulted in more fungal infections avoided.